AstraZeneca Publishes More Positive Data on Covid Antibody Treatment
- Six-month follow-up analysis improved trial results for drug
- Cocktail was effective at preventing virus and limiting impact
This article is for subscribers only.
AstraZeneca Plc’s Covid-19 antibody cocktail was more than 80% successful at both preventing symptomatic disease for six months and stopping the illness from worsening, demonstrating its ability to provide strong and long-lasting protection.
The medicine reduced the risk of developing symptomatic Covid in high-risk people by 83% in one of the trials after a six-month follow-up, the company said Thursday. The other one, which involved outpatient participants with mild to moderate illness, found the cocktail cut the risk of severe disease or death by 88% if given within three days.